Lab Confirmation Tetsing Kit Market Overview
This Lab Confirmation Testing Kit market study offers a comprehensive analysis of the business models, key strategies, and respective market shares of some of the most prominent players in this landscape. Along with an in-depth commentary on the key influencing factors, market statistics in terms of revenues, segment-wise data, region-wise data, and country-wise data are offered in the full study. This study is one of the most comprehensive documentation that captures all the facets of the evolving Lab Confirmation Testing Kit market.
COVID-19, also known as coronavirus disease, is continuing to spread globally with confirmed cases now surpassing 9,60,000 cases. With skyrocketing confirmed incidences of COVID-19, pharma, healthcare workers, universities as well as institutes are working tirelessly day and night to discover or develop cure for the life-threatening virus.
A point of contention at this critical hour is testing rates. It is only through widespread testing that the spread of this lethal virus and other metrics such as infectiousness and mortality rates, can be effectively recorded. Thus, readily available test kits are an indispensable way of effectively fighting and curbing the pandemic.
WHO’s Initiative in Controlling the Situation
Aiming to identify research gaps and priorities for COVID-19, collaborating with GloPID-R, WHO has organized a Forum on 11-12 February, 2020. The Forum has recognized urgent need for access to accurate and standardized diagnostics for SARS-CoV-2 (the causative agent of COVID-19), deployable in decentralized settings, has been recognized as one of the eight immediate research needs.
The Centers for Disease Control and Prevention (CDC), the US agency charged with tracking and investigating public health trends, is working in close co-operation with private labs to make more tests available. According to health experts, such an initiative would help capacitate to complete about 100 tests per day, which isn’t proportionate to the spread of this virus.
For more insights into the market, request a sample of this report@ https://www.futuremarketinsights.com/reports/sample/rep-gb-11270
The Urgent Need for Diagnostic Kits
At this point of time, an effective and efficient diagnosis of this alarmingly spreading virus would immensely help in curbing its spread all around the world. Developing a widely accessible, inexpensive point-of-care diagnostic kit requires an accountable leadership, decisive science-based governance, significant financing, and the application of reliable principle-based scientific protocols to determine whom to test, how to interpret results, and how best to treat and quarantine those infected.
Such measures would not only help contain the current COVD-19 epidemic; it can also create a system for developing similar tools to stop future pandemics. Thus, by taking the lead in creating such an infrastructure, the US can help itself and the rest of the world as well. According to Mediheroes, made-in-Korea diagnostic kits that have not won FDA’s emergency use authorization are likely to be used in USA.
Lab Confirmation Kits Being Developed by Various Companies
Numerous companies are racing to develop diagnostic kits – a new diagnostic tools identified by the Foundation for Innovative Diagnostics, a fifteen-minute test being developed by Chinese laboratories, a Duke University test being deployed in Singapore and diagnostic tests by CRISPR technology are a few noteworthy mentions. The US Food and Drug Administration (FDA) has an accelerated pathway for “emergently needed” diagnostic tools, but relies on developers need to conduct or sponsor themselves.
While in majority cases, patients experience minor symptoms, the disease can cause death under severe cases. Thus, medical companies worldwide are leaving no stones unturned to manufacture diagnostic kits for the alarmingly spreading coronavirus –
- BioFire Diagnostics – BioFire Respiratory Panels, also known as Film Array® Respiratory (RP & RP2) Panels, are tests that are developed to help medical clinics diagnose respiratory infections quickly. Such a development is anticipated to help treatment of the COVID-19 patients significantly.
- CephiedInc – CephiedInc has developed a test for the Coronavirus Strain (2019-nCoV) that is likely to deliver point-of-care results in just 30 minutes.
- GenMark Diagnostics, Inc – GenMark provided ePlex Research Use Only (RUO) test kits. The company thereby intends to submit an Emergency Use Authorization (EUA) to FDA (US Food and Drug Administration) for the ePlex SARS-CoV-2 test kits to conduct tests of COVID-19.
- “Master Mix”, created by Meridian Biosciences, is projected to work as the building blocks for COVID-19 and produce results in 45minutes to 1 hour. Their test kits are similar to tests done for influenza. These test kits have already been shipped from Germany to China.
For critical insights, request for PDF Brochure https://www.futuremarketinsights.com/reports/brochure/rep-gb-11270
About FMI:
Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.
Contact Us:
Mr. Debashish Roy
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
For Media Enquiries: press@futuremarketinsights.com
Website: https://www.futuremarketinsights.com